Novel quinoxalinone derivatives

Abstract

A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; X is NH, S or the like; Y is O or the like; the partial structure is, for example, the formula: B 1 , B 2 , . . . , B n−1 and B n , (in which n is 4, 5 or 6) are each independently CH, N or the like; B′ 1 , B′ 2 , . . . , B′ n−1 and B′ n (in which n is 4, 5 or 6) are each independently hydrogen or the like; and R is hydrogen, lower alkyl or the like.

1 - 16 . (canceled) 
     
     
         17 . A quinoxalinone derivative of the formula (I): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein;
 X is S; 
 Y is O or NR′, wherein R′ is hydrogen or lower alkyl; 
 the partial structure 
 
       
         
           
           
               
               
           
         
       
       is the following formula: 
       
         
           
           
               
               
           
         
         wherein 
         B 1 , B 2 , B 3 , B 4  and B 5  are each independently CH, CR 0 , N or O, wherein 
         when B 1 , B 2 , B 3 , B 4  and B 5  are each independently O, then B′ 1 , B′ 2 , B′ 3 , B′ 4  and B′ 5  are each taken together with B 1 , B 2 , B 3 , B 4  and B 5 , respectively, to form O, with the proviso that two or more members of B 1 , B 2 , B 3 , B 4  and B 5 , at the same time, are not taken together with B′ 1 , B′ 2 , B′ 3 , B′ 4  and B′ 5 , respectively, to form O; and 
         R 0  is lower alkyl, and 
         B′ 1 , B′ 2 , B′ 3 , B′ 4  and B′ 5  are each independently hydrogen, halogen, hydroxy, oxo, lower alkoxy, amino, lower alkylamino, di-lower alkylamino, lower alkyl or lower alkenyl, wherein 
         said lower alkyl and said lower alkenyl may be substituted with one or more, same or different substituents selected from the group consisting of hydroxy, lower alkoxy, amino and lower alkylamino, and 
         among B′ 1 , B′ 2 , B′ 3 , B′ 4  and B′ 5 , 
         B′ 1  and B′ 3  taken together with B 1 , B 2  and B 3 , 
         B′ 2  and B′ 4  taken together with B 2 , B 3  and B 4 , 
         B′ 3  and B′ 5  taken together with B 3 , B 4  and B 5 , 
         B′ 1  and B′ 4  taken together with B 1 , B 2 , B 3  and B 4 , or 
         B′ 2  and B′ 5  taken together with B 2 , B 3 , B 4  and B 5    
       
       may form a C 5 -C 6  cycloalkyl or an aliphatic heterocyclic group selected from the substituent group β 1  mentioned below, and said cycloalkyl and said aliphatic heterocyclic group may be substituted with one or more, same or different substituents selected from lower alkyl and the substituent group αmentioned below;
 R is hydrogen, lower alkyl, lower alkenyl, amino in which the nitrogen atom is di-substituted with R a  and R b , amino-lower alkyl in which the nitrogen atom is di-substituted with R a  and R b , or L, wherein R a  and R b  are each independently hydrogen, lower alkyl, lower alkoxyalkyl or halogenated lower alkyl, and L is L 1 -L 2 -L 3 , wherein L 1  is a single bond, —(CH 2 ) k1 —, —(CH 2 ) k1 —O—, or —(CH 2 ) k1 —NH—, in which k1 is an integer of 1 to 3; L 2  is a single bond or —(CH 2 ) k2 — in which k2 is an integer of 1 to 3; and L 3  is lower alkyl, lower alkoxy, C 3 -C 6  cycloalkyl, phenyl, pyridyl, pyrrolidinyl or piperidinyl, said lower alkyl, lower alkoxy, C 3 -C 6  cycloalkyl, phenyl, pyridyl, pyrrolidinyl or piperidinyl being optionally substituted with one or more fluorine atoms; or alternatively 
 R is a substituent selected from the substituent group α mentioned below, which may be substituted with one or more, same or different substituents selected from the substituent group γ mentioned below, or R is lower alkyl substituted with said substituent; or alternatively 
 R is a cyclic group selected from the substituent group β 2  mentioned below, which may be substituted with one or more, same or different substituents selected from a lower alkyl, the substituent group α mentioned below and the substituent group γ mentioned below and also which may be substituted with J, wherein J is J 1 -J 2 -J 3 ; J 1  is a single bond, —C(═O)—, —O—, —NH—, —NHCO—, —(CH 2 ) k3 — or —(CH 2 ) k3 —O—, in which k3 is an integer of 1 to 3); J 2  is a single bond or —(CH 2 ) k4 —, in which k4 is an integer of 1 to 3; and J 3  is lower alkyl, lower alkoxy, —CONR a R b , wherein R a  and R b  each have the same meaning as defined above, phenyl, pyridyl, pyrrolidinyl or piperidinyl, said lower alkyl, lower alkoxy, phenyl, pyridyl, pyrrolidinyl or piperidinyl being optionally substituted with one or more fluorine atoms, or R is lower alkyl substituted with said cyclic group, and 
 in the above, the substituent group α, the substituent group α 1 , the substituent group β 2  and the substituent group γ each have the meanings shown below: 
 the substituent group α is a member selected from the group consisting of hydroxy, hydroxy-lower alkyl, cyano, halogen, carboxyl, lower alkanoyl, lower alkoxycarbonyl, lower alkoxy, lower alkoxyalkyl, amino, lower alkylamino, lower alkylsulfonyl, halogenated lower alkyl, halogenated lower alkoxy, halogenated lower alkylamino, nitro and lower alkanoylamino, 
 the substituent group β 1  is a member selected from the group consisting of 
 
       
         
           
           
               
               
           
         
       
       the substituent group β 2  is a member selected from the group consisting of 
       
         
           
           
               
               
           
         
       
       the substituent group γ is a member selected from the group consisting of C 3 -C 6  cycloalkyl, lower alkyl substituted with C 3 -C 6  cycloalkyl, phenyl, lower alkyl substituted with phenyl, pyridyl, pyrrolidinyl and piperidinyl, said C 3 -C 6  cycloalkyl, phenyl, pyridyl, pyrrolidinyl and piperidinyl being optionally substituted with one or more fluorine atoms. 
     
     
         18 . The compound according to  claim 17  or a pharmaceutically acceptable salt thereof, wherein;
 Y is O.   
     
     
         19 . The compound according to  claim 18  or a pharmaceutically acceptable salt thereof, wherein;
 B 1 , B 2 , B 3 , B 4  and B 5  are each independently CH; or   B 1 , B 2 , B 4  and B 5  are each independently CH, and B 3  is N or O.   
     
     
         20 . The compound according to  claim 19  or a pharmaceutically acceptable salt thereof, wherein;
 the substituent group α is selected from hydroxy, hydroxy-lower alkyl, halogen, lower alkoxycarbonyl, lower alkoxy, lower alkoxyalkyl, lower alkylamino, methyl substituted with one to three fluorine atoms, methoxy substituted with one to three fluorine atoms and lower alkylamino substituted with one to three fluorine atoms; and the substituent group β 1  is   
       
         
           
           
               
               
           
         
       
     
     
         21 . The compound according to  claim 20  or a pharmaceutically acceptable salt thereof, wherein;
 B 1 , B 2 , B 4  and B 5  are each independently CH, B 3  is N, and all of B′ 1 , B′ 2 , B′ 3 , B′ 4  and B′ 5  are hydrogen; or   one of B′ 1 , B′ 2 , B′ 3 , B′ 4  and B′ 5  is lower alkyl or lower alkenyl, and all the others are hydrogen; or   at least two of B′ 1 , B′ 2 , B′ 3 , B′ 4  and B′ 5  are each independently lower alkyl or lower alkenyl, and all the others are hydrogen; or   among B′ 1 , B′ 2 , B′ 3 , B′ 4  and B′ 5 ,   B′ 1  and B′ 3  taken together with B 1 , B 2  and B 3 ,   B′ 2  and B′ 4  taken together with B 2 , B 3  and B 4 , or   B′ 3  and B′ 5  taken together with B 3 , B 4  and B 5 ,   form an aliphatic heterocycle group selected from the substituent group β 1 , wherein said aliphatic heterocycle may be substituted with one or more, same or different substituents selected from lower alkyl and the substituent group α,   and the others are hydrogen, lower alkyl or lower alkenyl.   
     
     
         22 . The compound according to any one of  claim 21  or a pharmaceutically acceptable salt thereof, wherein;
 the R binds to quinoxalinone as described in the following formula:   
       
         
           
           
               
               
           
         
       
     
     
         23 . The compound according to  claim 22  or a pharmaceutically acceptable salt thereof, wherein;
 R is hydrogen, amino-lower alkyl in which the nitrogen atom is di-substituted with R a  and R b , or L, wherein R a  and R b  are each independently lower alkyl, and L is L 1 -L 2 -L 3 , wherein L 1  is a single bond, —(CH 2 ) k1 —, —(CH 2 ) k1 —O— or —(CH 2 ) k1 —NH—, in which k1 is an integer of 1 or 2; L 2  is a single bond or —(CH 2 ) k2 —, in which k2 is an integer of 1 or 2; and L 3  is lower alkoxy or C 3 -C 6  cycloalkyl; or   R is a cyclic group selected from the substituent group β 2 , which may be substituted with one or more, same or different substituents selected from lower alkyl and the substituent group α, or R is lower alkyl substituted with said cyclic group, wherein the substituent group β 2  is selected from   
       
         
           
           
               
               
           
         
       
       and the substituent group α is selected from halogen, lower alkoxy, lower alkoxyalkyl, methyl substituted with one to three fluorine atoms, and methoxy substituted with one to three fluorine atoms; or lower alkyl substituted with a substituent selected from the group consisting of lower alkylamino and lower alkylamino substituted with one to three fluorine atoms. 
     
     
         24 . The compound according to  claim 18  or a pharmaceutically acceptable salt thereof, wherein;
 the partial structure   
       
         
           
           
               
               
           
         
       
       is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
       wherein R″ is hydrogen or methyl; and
 R is selected from the group consisting of 
 
       
         
           
           
               
               
           
         
       
     
     
         25 . The compound according to  claim 17  or a pharmaceutically acceptable salt thereof, wherein;
 the quinoxalinone derivative is   
       
         
           
           
               
               
           
         
       
     
     
         26 . A pharmaceutical composition comprising a quinoxalinone derivative according to  claim 17  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         27 . A pharmaceutical composition comprising a quinoxalinone derivative according to  claim 18  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         28 . A pharmaceutical composition comprising a quinoxalinone derivative according to  claim 19  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         29 . A pharmaceutical composition comprising a quinoxalinone derivative according to  claim 20  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         30 . A pharmaceutical composition comprising a quinoxalinone derivative according to  claim 21  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         31 . A pharmaceutical composition comprising a quinoxalinone derivative according to  claim 22  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         32 . A pharmaceutical composition comprising a quinoxalinone derivative according to  claim 23  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         33 . A pharmaceutical composition comprising a quinoxalinone derivative according to  claim 24  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         34 . A pharmaceutical composition comprising a quinoxalinone derivative according to  claim 25  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         35 . A method of inhibiting Cdk4, which comprises administering to a patient in need thereof a therapeutically effective amount of a quinoxalinone derivative according to  claim 17  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         36 . A method of inhibiting Cdk4, which comprises administering to a patient in need thereof a therapeutically effective amount of a quinoxalinone derivative according to  claim 18  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         37 . A method of inhibiting Cdk4, which comprises administering to a patient in need thereof a therapeutically effective amount of a quinoxalinone derivative according to  claim 19  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         38 . A method of inhibiting Cdk4, which comprises administering to a patient in need thereof a therapeutically effective amount of a quinoxalinone derivative according to  claim 20  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         39 . A method of inhibiting Cdk4, which comprises administering to a patient in need thereof a therapeutically effective amount of a quinoxalinone derivative according to  claim 21  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         40 . A method of inhibiting Cdk4, which comprises administering to a patient in need thereof a therapeutically effective amount of a quinoxalinone derivative according to  claim 22  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         41 . A method of inhibiting Cdk4, which comprises administering to a patient in need thereof a therapeutically effective amount of a quinoxalinone derivative according to  claim 23  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         42 . A method of inhibiting Cdk4, which comprises administering to a patient in need thereof a therapeutically effective amount of a quinoxalinone derivative according to  claim 24  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         43 . A method of inhibiting Cdk4, which comprises administering to a patient in need thereof a therapeutically effective amount of a quinoxalinone derivative according to  claim 25  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         44 . A method for treatment of cancer selected from the group consisting of glioma (blastoma), breast, lung, gastrointestinal, endometrial, leukemia, head and neck, liver, ovary or testicular, and mesothelima, which comprises administering to a patient in need thereof a quinoxalinone derivative according to  claim 17  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         45 . A method for treatment of cancer selected from the group consisting of glioma (blastoma), breast, lung, gastrointestinal, endometrial, leukemia, head and neck, liver, ovary or testicular, and mesothelima, which comprises administering to a patient in need thereof a quinoxalinone derivative according to  claim 18  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         46 . A method for treatment of cancer selected from the group consisting of glioma (blastoma), breast, lung, gastrointestinal, endometrial, leukemia, head and neck, liver, ovary or testicular, and mesothelima, which comprises administering to a patient in need thereof a quinoxalinone derivative according to  claim 19  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         47 . A method for treatment of cancer selected from the group consisting of glioma (blastoma), breast, lung, gastrointestinal, endometrial, leukemia, head and neck, liver, ovary or testicular, and mesothelima, which comprises administering to a patient in need thereof a quinoxalinone derivative according to  claim 20  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         48 . A method for treatment of cancer selected from the group consisting of glioma (blastoma), breast, lung, gastrointestinal, endometrial, leukemia, head and neck, liver, ovary or testicular, and mesothelima, which comprises administering to a patient in need thereof a quinoxalinone derivative according to  claim 21  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         49 . A method for treatment of cancer selected from the group consisting of glioma (blastoma), breast, lung, gastrointestinal, endometrial, leukemia, head and neck, liver, ovary or testicular, and mesothelima, which comprises administering to a patient in need thereof a quinoxalinone derivative according to  claim 22  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         50 . A method for treatment of cancer selected from the group consisting of glioma (blastoma), breast, lung, gastrointestinal, endometrial, leukemia, head and neck, liver, ovary or testicular, and mesothelima, which comprises administering to a patient in need thereof a quinoxalinone derivative according to  claim 23  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         51 . A method for treatment of cancer selected from the group consisting of glioma (blastoma), breast, lung, gastrointestinal, endometrial, leukemia, head and neck, liver, ovary or testicular, and mesothelima, which comprises administering to a patient in need thereof a quinoxalinone derivative according to  claim 24  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent. 
     
     
         52 . A method for treatment of cancer selected from the group consisting of glioma (blastoma), breast, lung, gastrointestinal, endometrial, leukemia, head and neck, liver, ovary or testicular, and mesothelima, which comprises administering to a patient in need thereof a quinoxalinone derivative according to  claim 25  as an active ingredient, together with a pharmaceutically acceptable carrier or diluent.